福巴替尼和培米替尼的区别？

Both fobatinib and pemetinib can be used to treat cholangiocarcinoma, but there are differences between them in terms of manufacturer, drug price, usage and dosage, and adverse reactions.

Manufacturer

Forbatinib was developed by Taiho Oncology and Taiho Pharmaceutical, and the manufacturer is Japan's Taiho Oncology (Japan's Taiho Pharmaceutical). The manufacturer of pemetinib is Incyte Corporation of the United States.

drug prices

It is not currently available in the country, so it cannot be purchased in domestic pharmacies and hospital pharmacies. Patients may consider choosing forbatinib, which is available overseas. The reference price of 16MG*28 pieces, 20MG*35 pieces, and 12MG*21 pieces is about 240,576$.

Already on the market in China, the reference price of the Hong Kong version of Pemazyre 13.5mg*14 tablets is about $69,600, and the reference price of the Lao Namtha version of Pemazyre 4.5mg*21 tablets is about $4,000 per box.

However, due to the impact of foreign exchange rate fluctuations, drug prices also vary. For specific prices and purchasing methods, please consult the medical companion travel service.

Usage and dosage

The recommended dose is 20mg, which is 5 tablets of 4g each, taken orally once a day and taken at about the same time. Tablets should be swallowed whole and do not crush, chew, split or dissolve. If the patient misses a forbatinib dose for more than 12 hours or experiences vomiting, continue with the next scheduled dose.

The recommended dose of pemetinib is 13.5 mg orally for 14 days, followed by 7 days off in a 21-day cycle until disease progression or intolerable toxicity occurs.

adverse reactions

Common adverse reactions of forbatinib include methamine, constipation, diarrhea, dry eyes, nausea, musculoskeletal pain, fatigue, dry mouth, alopecia, palmar and plantar red sensation syndrome, ataxia, stomatitis, urinary tract infection, abdominal pain, dry skin, joint pain, loss of appetite, vomiting, and elevated phosphate and red blood. Decreased protein, increased glucose, decreased potassium content, decreased albumin, increased creatinine, increased alkaline phosphatase, increased calcium, decreased sodium, decreased phosphate, increased alanine aminotransferase, decreased lymphocytes, increased aspartate aminotransferase, decreased platelets, increased activated partial thromboplastin time, etc.

Common adverse reactions of pemetinib include changes in taste, vomiting, hair loss, loss of appetite, muscle cramps, mouth sores, weight loss, eye floaters, fatigue, painful urination, stomach pain, dry mouth and/or dry skin, swelling and pain in limbs or joints, decreased urine output or rapid heartbeat, seeing flashes of light or other vision changes, onychomycosis, headache, blurred vision, numbness or dry mouth.

There are also differences in treatment effects between fobartinib and pemetinib. It is recommended that patients choose medication according to their own conditions under the guidance of a doctor.

Recommended related articles: